Dagco Inc. Has $4.35 Million Stock Holdings in SELLAS Life Sciences Group, Inc. $SLS

Dagco Inc. increased its holdings in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 78.1% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,028,780 shares of the company’s stock after purchasing an additional 451,240 shares during the quarter. SELLAS Life Sciences Group makes up 0.9% of Dagco Inc.’s investment portfolio, making the stock its 23rd largest position. Dagco Inc.’s holdings in SELLAS Life Sciences Group were worth $4,352,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Anson Funds Management LP lifted its stake in SELLAS Life Sciences Group by 2,093.8% in the 3rd quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock worth $9,713,000 after acquiring an additional 5,757,938 shares in the last quarter. Everhart Financial Group Inc. grew its stake in SELLAS Life Sciences Group by 40.8% during the 4th quarter. Everhart Financial Group Inc. now owns 466,216 shares of the company’s stock valued at $1,758,000 after acquiring an additional 135,066 shares in the last quarter. Trustmark Bank Trust Department purchased a new position in SELLAS Life Sciences Group during the 3rd quarter valued at about $59,000. Money Concepts Capital Corp acquired a new position in shares of SELLAS Life Sciences Group in the 4th quarter valued at about $40,000. Finally, CWM LLC increased its holdings in shares of SELLAS Life Sciences Group by 124.7% in the 4th quarter. CWM LLC now owns 11,782 shares of the company’s stock valued at $44,000 after purchasing an additional 6,538 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on SLS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. Maxim Group upped their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Price Performance

SELLAS Life Sciences Group stock opened at $10.53 on Friday. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $11.06. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -45.78 and a beta of 2.50. The firm has a fifty day moving average price of $6.99 and a two-hundred day moving average price of $5.10.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.